PMID- 36326083
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230215
IS  - 1744-5094 (Electronic)
IS  - 1381-6810 (Linking)
VI  - 43
IP  - 6
DP  - 2022 Dec
TI  - Retinal and optic nerve relapse in retinoblastoma secondary to epiretinal and 
      epipapillary vitreous seeds implantation documented by optical coherence 
      tomography.
PG  - 850-854
LID - 10.1080/13816810.2022.2141801 [doi]
AB  - BACKGROUND: Retinal retinoblastoma growth phenotypes can be endophytic, 
      exophytic, diffuse infiltrating or anterior diffuse. Herein, we describe a novel 
      tumor growth pattern in two patients. MATERIAL AND METHODS: Imaging with 
      spectral-domain optical coherence tomography (SD-OCT). RESULTS: Both cases were 
      diagnosed with unilateral group D retinoblastoma treated with first-line or 
      bridge intra-arterial chemotherapy (IAC). Case 1 had a new 
      intravitreal/epiretinal relapse 3 months after brachytherapy and intravitreal 
      chemotherapy. SD-OCT showed a disruption of the inner limiting membrane (INL) 
      underneath a parapapillary epiretinal seed. The intravitreal/epiretinal disease 
      completely regressed with intravitreal melphalan. Three months later, an isolated 
      intraretinal growth was documented on SD-OCT at the site of previously INL 
      disruption, which was treated by thermotherapy. He remained disease-free at 
      1-year follow-up with 0.6 visual acuity. Case 2 was seen 2 months after treatment 
      interruption due to the COVID-19 pandemic. Fundus examination showed a massive 
      intravitreal/epipapillary invasion completely obscuring the papilla. Salvage 
      treatment of this seeing eye consisted of combined intra-arterial and 
      intravitreal melphalan and topotecan injections. An infraclinical papillary 
      regrowth 4 months later was treated with additional IAC. Six months later, 
      enucleation was performed due to an infraclinical papillary relapse with 
      suspicion of intralaminar invasion. Histopathology showed retrolaminar optic 
      nerve invasion with tumor-free surgical section. The child received four cycles 
      of adjuvant chemotherapy and remained disease-free at 1-year follow-up. 
      CONCLUSION: Epiretinal/epipapillary vitreous seeding can be the source of a 
      secondary intraretinal/optic nerve head relapse. SD-OCT is instrumental to follow 
      such cases. Enucleation remains the safest option if secondary optic nerve 
      invasion is suspected.
FAU - Stathopoulos, Christina
AU  - Stathopoulos C
AD  - Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, 
      Lausanne, Switzerland.
FAU - Tripathy, Devjyoti
AU  - Tripathy D
AD  - Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, 
      Lausanne, Switzerland.
AD  - LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.
FAU - Moulin, Alexandre
AU  - Moulin A
AD  - Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, 
      Lausanne, Switzerland.
FAU - Beck-Popovic, Maja
AU  - Beck-Popovic M
AUID- ORCID: 0000-0001-9502-5697
AD  - Unit of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Vaudois, 
      Lausanne, Switzerland.
FAU - Munier, Francis L
AU  - Munier FL
AUID- ORCID: 0000-0002-8928-1050
AD  - Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, 
      Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221103
PL  - England
TA  - Ophthalmic Genet
JT  - Ophthalmic genetics
JID - 9436057
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Retinoblastoma/diagnosis
MH  - *Retinal Neoplasms/diagnosis
MH  - Tomography, Optical Coherence
MH  - Melphalan/therapeutic use
MH  - *Brachytherapy/methods
MH  - Pandemics
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Neoplasm Recurrence, Local/pathology
MH  - *COVID-19
MH  - Optic Nerve
MH  - Retrospective Studies
MH  - Intravitreal Injections
OTO - NOTNLM
OT  - Retinoblastoma
OT  - optical coherence tomography
OT  - relapse
OT  - treatment
EDAT- 2022/11/04 06:00
MHDA- 2023/01/27 06:00
CRDT- 2022/11/03 06:53
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2022/11/03 06:53 [entrez]
AID - 10.1080/13816810.2022.2141801 [doi]
PST - ppublish
SO  - Ophthalmic Genet. 2022 Dec;43(6):850-854. doi: 10.1080/13816810.2022.2141801. 
      Epub 2022 Nov 3.